These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8349724)

  • 1. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A; von Angerer E
    J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.
    Chandolia RK; Weinbauer GF; Simoni M; Behre HM; Nieschlag E
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):547-55. PubMed ID: 1759544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casodex: preclinical studies and controversies.
    Furr BJ
    Ann N Y Acad Sci; 1995 Jun; 761():79-96. PubMed ID: 7625752
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J; Singh SM; Labrie F
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
    Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
    Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
    Freeman SN; Mainwaring WI; Furr BJ
    Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM; She Y; Lee F; Chen J; Scher HI
    Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
    Wang LG; Mencher SK; McCarron JP; Ferrari AC
    Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
    Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
    Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen.
    Furr BJ; Valcaccia B; Curry B; Woodburn JR; Chesterson G; Tucker H
    J Endocrinol; 1987 Jun; 113(3):R7-9. PubMed ID: 3625091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
    Sivko AV; Prokhorov AV
    Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.